InnoCare Pharma Limited (HKG:9969)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 29.89B -10.1% |
| Revenue (ttm) | 3.21B +110.5% |
| Net Income | 1.06B |
| EPS | 0.58 |
| Shares Out | 1.70B |
| PE Ratio | 24.80 |
| Forward PE | 76.49 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,152,000 |
| Open | 14.43 |
| Previous Close | 14.47 |
| Day's Range | 14.19 - 14.95 |
| 52-Week Range | 9.65 - 20.18 |
| Beta | 0.39 |
| Analysts | Strong Buy |
| Price Target | 18.99 (+28.4%) |
| Earnings Date | Oct 27, 2026 |
About InnoCare Pharma
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom’s macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thro... [Read more]
Analyst Summary
According to 9 analysts, the average rating for 9969 stock is "Strong Buy." The 12-month stock price target is $18.99, which is an increase of 28.40% from the latest price.
News
China's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billion
Chinese drugmaker InnoCare Pharma said on Thursday it entered into a research collaboration and license agreement with Eli Lilly that could be worth up to about $3.35 billion.
InnoCare Pharma Earnings Call Transcript: Q2 2026
Revenue grew 55.5% year-over-year to RMB 1.14 billion, with net profit reaching RMB 240 million and strong cash reserves supporting R&D. Multiple late-stage assets advanced in oncology and autoimmune diseases, with several NDAs and phase III studies underway. Guidance for over 35% full-year drug sales growth reaffirmed.
InnoCare Pharma Earnings release: Q2 2026
InnoCare Pharma released its Q2 2026 earnings on August 24, 2026, summarizing the period's financial results.
InnoCare Pharma Slides: Q2 2026
InnoCare Pharma has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 24, 2026.
InnoCare Pharma Quarterly report: Q2 2026
InnoCare Pharma has published its Q2 2026 quarterly earnings report on August 24, 2026.
China's Innocare's psoriasis drug meets main goal in late-stage trial
China-based Innocare Pharma said on Monday the Phase III trial of fadeucravacitinib, an experimental treatment for moderate-to-severe plaque psoriasis, has met its primary endpoint.
InnoCare Announces Publication in STTT (IF=81.2) of Phase 3 Results Showing Orelabrutinib Significantly Prolonged Progression-Free Survival in Treatment-Naïve CLL/SLL
BEIJING, July 14, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428) today announced that Signal Transduction and Targeted Therapy (STTT), a Nature Portfolio journal, published a pape...
InnoCare Announces First Patient Dosed in Clinical Trial of Novel CDH17 targeted ADC ICP-B208 in China
BEIJING, July 05, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today ...
Phase IIb Study Results of InnoCare's Orelabrutinib in Patients with SLE Presented at 2026 EULAR
BEIJING, June 05, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today ...
ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released
BEIJING, June 02, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today ...
InnoCare Pharma upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley upgraded InnoCare Pharma (INCPF) to Overweight from Equal Weight with a price target of HK$17, down from HK$19.60. The valuation of China biotech stocks has “reset to a…
InnoCare Announces the Acceptance of New Drug Application for Orelabrutinib in Primary Immune Thrombocytopenia in China
BEIJING, May 28, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today th...
InnoCare Announces Approval of Orelabrutinib in Australia
BEIJING, May 27, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that orelabrutinib...
2026 ASCO | Pivotal Data of InnoCare's Novel BCL2 Inhibitor Mesutoclax Released
BEIJING, May 22, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today t...
InnoCare Announce First Subject Dosed in Phase 1 Clinical Trial of ICP-054, a Novel Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
- Phase 1 trial designed to evaluate the safety, tolerability, and pharmacokinetic properties of ICP-054 (ZB021) in healthy volunteers - Phase 1 SAD and MAD data expected by year-end 2026
InnoCare Announces Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Sjögren's Syndrome in China
BEIJING, May 07, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today th...
InnoCare Announces Approval of Clinical Trial of Novel CDH7 targeted ADC ICP-B208 in China
BEIJING, May 06, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today th...
InnoCare Announces First Patient Dosed in Phase III Trial of Orelabrutinib for SLE
Orelabrutinib is the first BTKi to demonstrate significant efficacy in a Phase II clinical trial for SLE, which affects around 8 million people worldwide.
InnoCare Releases 2026 Q1 Results: Strong Revenue Growth and Sustained Profitability
BEIJING, April 23, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428) today announced its results and business highlights for the first quarter of 2026 as of 31 March 2026. Over the p...
InnoCare Pharma Earnings release: Q1 2026
InnoCare Pharma released its Q1 2026 earnings on April 23, 2026, summarizing the period's financial results.
InnoCare Pharma Slides: Q1 2026
InnoCare Pharma has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 23, 2026.
InnoCare Releases 2025 Results and Business Highlights, Achieving First Annual Profit
BEIJING, March 25, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the annual resul...
InnoCare Pharma Earnings Call Transcript: Q4 2025
Achieved first annual profit and 135% revenue growth, driven by strong product sales and major BD deals. Robust pipeline progress in oncology and autoimmune diseases, with multiple regulatory approvals and global partnerships. Drug sales expected to grow over 35% in 2026.
InnoCare Pharma Earnings release: Q4 2025
InnoCare Pharma released its Q4 2025 earnings on March 25, 2026, summarizing the period's financial results.
InnoCare Pharma Slides: Q4 2025
InnoCare Pharma has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 25, 2026.